LLY

710.61

+0.3%↑

JNJ

179.04

+0.08%↑

ABBV

210.25

+0.41%↑

UNH

306.92

+1.28%↑

AZN

80.93

+0.65%↑

LLY

710.61

+0.3%↑

JNJ

179.04

+0.08%↑

ABBV

210.25

+0.41%↑

UNH

306.92

+1.28%↑

AZN

80.93

+0.65%↑

LLY

710.61

+0.3%↑

JNJ

179.04

+0.08%↑

ABBV

210.25

+0.41%↑

UNH

306.92

+1.28%↑

AZN

80.93

+0.65%↑

LLY

710.61

+0.3%↑

JNJ

179.04

+0.08%↑

ABBV

210.25

+0.41%↑

UNH

306.92

+1.28%↑

AZN

80.93

+0.65%↑

LLY

710.61

+0.3%↑

JNJ

179.04

+0.08%↑

ABBV

210.25

+0.41%↑

UNH

306.92

+1.28%↑

AZN

80.93

+0.65%↑

Strona główna・Stock List・Fate Therapeutics Inc

Fate Therapeutics Inc

Closed

SectorHealthcare

1.14 2.7

Buy Sell

Overview

Share price change

24h

Current

Min

1.09

Max

1.16

Key metrics
By Trading Economics
Income	3.6M -34M
Sales	278K 1.9M
Profit margin	-1,786.576
Employees	181
EBITDA	979K -37M

Recommendations
By TipRanks
Recommendations	Buy
12 Months Forecast	+215.32% upside

Dividends
By Dow Jones
Next Earnings	10 lis 2025

Market Stats
By TradingEconomics
Market Cap	31M 138M
Previous open	-1.56
Previous close	1.14

News Sentiment

By Acuity

50%

169 / 372 Ranking in Healthcare

Technical Score

By Trading Central

Confidence

Very Strong Bearish Evidence

0.9101 / 1.14 Support & Resistance

Fate Therapeutics Inc Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

22 sie 2025, 23:09 UTC

Acquisitions, Mergers, Takeovers

Trump Says U.S. Will Take Nearly 10% Equity Stake in Intel -- 4th Update

22 sie 2025, 22:02 UTC

Acquisitions, Mergers, Takeovers

Agreement Could Also Lead to Deeper Collaboration Between CSX, BNSF

22 sie 2025, 22:02 UTC

Acquisitions, Mergers, Takeovers

Some Analysts Say Agreement Suggests Lack of Confidence in Merger

22 sie 2025, 22:02 UTC

Acquisitions, Mergers, Takeovers

CSX, BNSF Intermodal Pact Draws Competing Views on Merger Possibility

22 sie 2025, 22:02 UTC

Acquisitions, Mergers, Takeovers

CSX, BNSF Pact Sparks Debate on Whether Another Rail Merger Is Approaching -- Analysis

22 sie 2025, 22:02 UTC

Acquisitions, Mergers, Takeovers

Pact Could Show Regulators That Transcontinental Service Can Come Without Merger

22 sie 2025, 21:23 UTC

Market Talk

Moody's Lowers Outlook on Austria to Negative From Stable -- Market Talk

22 sie 2025, 21:18 UTC

Market Talk

US Economic Growth Seen Slowing This Year -- Market Talk

22 sie 2025, 21:18 UTC

Acquisitions, Mergers, Takeovers

U.S. Takes 10% Stake in Intel -- Barrons.com

22 sie 2025, 21:03 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

22 sie 2025, 21:03 UTC

Market Talk

Mexican Stocks Close At Record High -- Market Talk

22 sie 2025, 20:58 UTC

Market Talk

US General Government Deficit Expected to Rise in 2026, 2027 -- Market Talk

22 sie 2025, 20:57 UTC

Acquisitions, Mergers, Takeovers

Intel: Government's Investment in Intel Will Be a Passive Ownership, With No Bd Representation or Other Governance or Info Rights >INTC

22 sie 2025, 20:57 UTC

Acquisitions, Mergers, Takeovers

Intel: Government Also Agrees to Vote With the Company's Bd of Directors on Matters Requiring Shareholder Approval, With Limited Exceptions >INTC

22 sie 2025, 20:57 UTC

Acquisitions, Mergers, Takeovers

Intel: Government Equity Stake Will Be Funded by Remaining $5.7B in Grants Previously Awarded, But Not Yet Paid, Under U.S. CHIPS and Science Act and $3.2B Awarded as Part of Secure Enclave Program >INTC

22 sie 2025, 20:57 UTC

Acquisitions, Mergers, Takeovers

Intel: Government Agrees to Purchase 433.3M Primary Shrs of Intel Common Stk at a Price of $20.47 per Shr, Equivalent to a 9.9% Stake in Co >INTC

22 sie 2025, 20:57 UTC

Acquisitions, Mergers, Takeovers

Intel: U.S. Government to Make $8.9B Investment in Intel Common Stk as Co Builds Upon Its More Than $100B Expansion of Resilient Semiconductor Supply Chain >INTC

22 sie 2025, 20:57 UTC

Acquisitions, Mergers, Takeovers

Intel: Intel and Trump Admin Reach Historic Agreement to Accelerate Amer Technology and Manufacturing Leadership

22 sie 2025, 20:56 UTC

Earnings

These Stocks Moved the Most Today: Nvidia, Builders FirstSource, Zoom, Intuit, Workday, BJ's, Ubiquiti, and More -- Barrons.com

22 sie 2025, 20:55 UTC

Earnings

These Stocks Are Moving the Most Today: Nvidia, Builders FirstSource, Zoom, Intuit, Workday, BJ's, Ubiquiti, and More -- Barrons.com

22 sie 2025, 20:50 UTC

Market Talk

Earnings

Tech, Media & Telecom Roundup: Market Talk

22 sie 2025, 20:50 UTC

Market Talk

Acquisitions, Mergers, Takeovers

Basic Materials Roundup: Market Talk

22 sie 2025, 20:41 UTC

Acquisitions, Mergers, Takeovers

U.S. Has 10% Stake in Intel, Lutnick Says -- Barrons.com

22 sie 2025, 20:24 UTC

Acquisitions, Mergers, Takeovers

Trump Says U.S. Will Take Nearly 10% Equity Stake in Intel -- 3rd Update

22 sie 2025, 20:16 UTC

Acquisitions, Mergers, Takeovers

CSX and Warren Buffett's BNSF Made News. Why Investors Are Disappointed. -- Barrons.com

22 sie 2025, 19:19 UTC

Market Talk

Boeing to Restart Talks With Defense Workers' Union Monday -- Market Talk

22 sie 2025, 19:10 UTC

Market Talk

Oil Futures Gain as Russia-Ukraine Peace Seems Distant -- Market Talk

22 sie 2025, 19:06 UTC

Market Talk

U.S. Natural Gas Extends Losses as Summer Nears an End -- Market Talk

22 sie 2025, 19:03 UTC

Market Talk

Lower Borrowing Rates Elusive Even if Fed Cuts -- Market Talk

22 sie 2025, 18:52 UTC

Acquisitions, Mergers, Takeovers

Trump Says U.S. Will Take Nearly 10% Equity Stake in Intel -- 2nd Update

Peer Comparison

Price change

Fate Therapeutics Inc Forecast

Price Target

By TipRanks

215.32% upside

12 Months Forecast

Average 3.5 USD 215.32%

High 6 USD

Low 2 USD

Based on 7 Wall Street analysts offering 12 month price targets forFate Therapeutics Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Buy

7 ratings

Buy

Hold

Sell

Based on 7 analysts giving stock ratings to Fate Therapeutics Inc - Dist in the past 3 months.

Technical Score

By Trading Central

0.9101 / 1.14Support & Resistance

Recent bearish events outweigh bullish events.

All events are bullish.

There are no events.

Sentiment

By Acuity

169 / 372 Ranking in Healthcare

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About Fate Therapeutics Inc

Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT576 to treat multiple myeloma, and FT522, to treat lymphoma and autoimmune disorders. Its CAR T-cell programs include FT819 to treat hematologic malignancies and solid tumors, and FT825 to treat solid tumors. The company has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of off-the-shelf, iPSC-derived CAR T-cell product candidates for the treatment of cancer. Fate Therapeutics, Inc. was incorporated in 2007 and is headquartered in San Diego, California.